CFTR lifecycle map—A systems medicine model of CFTR maturation to predict possible active compound combinations

Abstract

Different causative therapeutics for CF patients have been developed. There are still no mutation‐specific therapeutics for some patients, especially those with rare CFTR mutations. For this purpose, high‐throughput screens have been performed which result in various candidate com-pounds, with mostly unclear modes of action. In order to elucidate the mechanism of action for promising candidate substances and to be able to predict possible synergistic effects of substance combinations, we used a systems biology approach to create a model of the CFTR maturation pathway in cells in a standardized, human‐ and machine‐readable format. It is composed of a core map, manually curated from small‐scale experiments in human cells, and a coarse map including interac-tors identified in large‐scale efforts. The manually curated core map includes 170 different molecular entities and 156 reactions from 221 publications. The coarse map encompasses 1384 unique proteins from four publications. The overlap between the two data sources amounts to 46 proteins. The CFTR Lifecycle Map can be used to support the identification of potential targets inside the cell and elucidate the mode of action for candidate substances. It thereby provides a backbone to structure available data as well as a tool to develop hypotheses regarding novel therapeutics.